Updated Guidelines on the Management of Cytomegalovirus Reactivation in Patients with Chronic Lymphocytic Leukemia Treated with Alemtuzumab.

MLA

O’Brien, Susan M., et al. “Updated Guidelines on the Management of Cytomegalovirus Reactivation in Patients with Chronic Lymphocytic Leukemia Treated with Alemtuzumab.” Clinical Lymphoma & Myeloma, vol. 7, no. 2, Sept. 2006, pp. 125–30. EBSCOhost, widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edb&AN=52843676&authtype=sso&custid=ns315887.

APA

O’Brien, S. M., Keating, M. J., & Mocarski, E. S. (2006). Updated Guidelines on the Management of Cytomegalovirus Reactivation in Patients with Chronic Lymphocytic Leukemia Treated with Alemtuzumab. Clinical Lymphoma & Myeloma, 7(2), 125–130.

Chicago

O’Brien, Susan M., Michael J. Keating, and Edward S. Mocarski. 2006. “Updated Guidelines on the Management of Cytomegalovirus Reactivation in Patients with Chronic Lymphocytic Leukemia Treated with Alemtuzumab.” Clinical Lymphoma & Myeloma 7 (2): 125–30. http://widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edb&AN=52843676&authtype=sso&custid=ns315887.